Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme

By sjmartinez • February 1, 2023

Dougados M, Charles-Schoeman C, Szekanecz Z, Giles JT, Ytterberg SR, Bhatt DL, Koch GG, Vranic I, Wu J, Wang C, Kwok K, Menon S, Connell CA, Yndestad A, Rivas JL, Buch MH. Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme. Ann Rheum Dis. 2023 Jan 31:ard-2022-223406. doi: 10.1136/ard-2022-223406. Epub ahead of print. PMID: 36720582.

Tags: Antirheumatic Agents, Arthritis, cardiovascular diseases, Publications, Rheumatoid, Rheumatology

Clinical Outcomes and Health Care Costs in Patients Hospitalized With Heart Failure and Transthyretin Amyloid Cardiomyopathy: Findings From GWTG-HF

Shoji S, Ikeaba U, Fonarow GC, Selvaraj S, Lewsey SC, Pandey A, Khouri MG, Alhanti B, McDermott JJ, Wright J, Vaduganathan M, Greene SJ. Clinical[...]

A practical approach to Cardiopulmonary Exercise Testing: from functional evaluation to adapted exercise prescription

Neunhaeuserer D, Gevaert AB, Hansen D, Battista F, Bauer P, Davos CH, Ermolao A, Sanz-de la Garza M, Guazzi M, Howden EJ, Laukkanen J, Mueller-Stegner[...]

Gut microbe-generated metabolite trimethylamine N-oxide and risk of abdominal aortic aneurysm: a cohort study

Li XS, Wang M, Wang Z, Fan B, Tian MY, Filippazzo J, Lee Y, Mallela DP, Mao K, Liu Y, Lemaitre RN, Xie V, Diaz[...]